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Abstract
Background: To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of
the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated
interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%–50% of patients. Interleukin 28B (IL28B)
genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we
studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer
immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control.
Methods and Findings: We genotyped chronic hepatitis C (CHC) genotype 1 patients with PegIFN/R treatment-induced
clearance (n= 417) and treatment failure (n= 493), and 234 individuals with spontaneous clearance, for HLA-C C1 versus C2,
presence of inhibitory and activating KIR genes, and two IL28B SNPs, rs8099917 and rs12979860. All individuals were
Europeans or of European descent. IL28B SNP rs8099917 ‘‘G’’ was associated with absence of treatment-induced clearance
(odds ratio [OR] 2.19, p= 1.2761028, 1.67–2.88) and absence of spontaneous clearance (OR 3.83, p= 1.71610214, 2.67–5.48)
of HCV, as was rs12979860, with slightly lower ORs. The HLA-C C2C2 genotype was also over-represented in patients who
failed treatment (OR 1.52, p= 0.024, 1.05–2.20), but was not associated with spontaneous clearance. Prediction of treatment
failure improved from 66% with IL28B to 80% using both genes in this cohort (OR 3.78, p= 8.8361026, 2.03–7.04). There was
evidence that KIR2DL3 and KIR2DS2 carriage also altered HCV treatment response in combination with HLA-C and IL28B.
Conclusions: Genotyping for IL28B, HLA-C, and KIR genes improves prediction of HCV treatment response. These findings
support a role for natural killer (NK) cell activation in PegIFN/R treatment-induced clearance, partially mediated by IL28B.
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Introduction
Studies of human genetics have been expected to alter clinical
management for many diseases, including infectious diseases. Yet,
to date, there are few examples of the use of such information in
routine clinical practice. One of the most promising examples,
identified in genome-wide analyses, is used to predict response to
treatment for hepatitis C, based on a single genetic variant.
Only 20%–30% of the ,170 million people infected with the
hepatitis C virus (HCV) recover spontaneously; the remainder
develop chronic infection [1] with a risk for developing cirrhosis,
liver failure, and hepatocellular carcinoma [2]. Current standard of
care with pegylated interferon-alpha and ribavirin (PegIFN/R)
achieves a sustained virological response (SVR) (HCV RNA
undetectable 6 mo post cessation of therapy) in 40%–50% of those
infected with the most common viral genotype, type 1, after 48 wk
[3]. Treatment is expensive and is associated with numerous side
effects, which sometimes require dose reduction and premature
treatment cessation, thus increasing the risk of treatment failure.
Host genotyping studies have the potential to identify genes and
therefore pathogenic processes important in viral clearance, enabling
a rational approach to design new drugs, and to identify patients who
will most likely respond to current and new treatments.
We and others previously used genome-wide association studies
(GWAS) to identify SNPs in the genetic region encoding IL28B,
which strongly influences treatment outcome [4–6] and spontane-
ous clearance [7]. Other genes associated with drug response have
not yet been identified in GWAS with genome-wide significance.
Variants in linkage with IL28B allow prediction of up to 64% for
failure to clear virus during therapy in cross-sectional cohorts [5].
The minor allele of SNP rs8099917 tags the nonresponse haplotype
in Asians and Caucasians, but not in African Americans. The minor
allele of SNP rs12979860 is on this haplotype in all ethnic groups,
and on other less significant haplotypes, so is used where African
Americans are in the patient cohort [8].
GWAS are dependent on SNPs tagging associated genetic
variants and cannot measure interactions because of the high
statistical penalty for multiple comparisons. Human leukocyte
antigen (HLA) and killer cell immunoglobulin-like receptors
(KIR) are highly polymorphic genetic loci whose gene proteins
interact with each other and for which proxy SNPs for their major
variants have yet to be identified. HLA-C molecules present
ligands for KIR2DL receptors, with a functionally relevant
dimorphism determining KIR specificity: HLA-C group 1 (HLA-
C1) alleles, identified by Ser77/Asp80 of the HLA-C alpha 1
domain, are ligands for the inhibitory receptors KIR2DL2 and
KIR2DL3 and the activating receptor KIR2DS2 [9,10]. HLA-C
group 2 (HLA-C2) alleles, identified by Asp77/Lys80, are
recognized by inhibitory KIR2DL1 and activating KIR2DS1
[9–12]. KIR2DL3 and its ligand, HLA-C1 has been associated
with an increased likelihood of spontaneous [13–15], and
treatment-induced HCV clearance [14,15]. This association is
attributed to differential natural killer (NK) cell activation and
function in the context of this KIR/HLA interaction [16]. SNPs
from the HLA-C coding regions showed weak associations with
SVR in our original GWAS [5].
The current study specifically addresses whether the IL28B and
KIR/HLA-C gene loci have separate, additive, or interactive effects
on HCV clearance (spontaneous or treatment induced). This
information is essential to better understand the role of IL28B
during HCV infection, to better predict response to therapy, and
potentially to allow better selection of patients for treatment.
Methods
Ethics Statement and Study Participants
Ethical approval was obtained from the Human Research
Ethics Committees of Sydney West Area Health Service and the
University of Sydney. All other sites had ethical approval from
their respective ethics committees. Written informed consent was
obtained from all participants. Characteristics of each cohort are
shown in Table 1. All treated patients were infected with genotype
1, received PegIFN/R, and had virological response determined
6 mo after completion of therapy. The diagnosis of chronic
hepatitis C (CHC) was based on appropriate serology and
presence of HCV RNA. All SVRs and non-SVR cases received
therapy for 48 wk except when HCV RNA was present with a ,2
log drop in HCV RNA level after 12-wk therapy. Patients were
excluded if they had been coinfected with either hepatitis B virus
or HIV or if they were not of European descent.
Samples from individuals with spontaneous clearance were
collected from Westmead Hospital in Sydney (n=149), the
Melbourne NETWORK study (n=31) [17], the Australian
ATACH study (n=18) [18], and Rheinische Friedrich-Wilhelms-
Universitaet, Bonn, Germany (n=36). Spontaneous clearance was
defined as HCV RNA negative and hepatitis C antibody positive
without undergoing hepatitis C treatment.
Genotyping
For HLA-C, samples were genotyped by multiplex PCR [19] to
two-digit resolution. For samples from Turin and those partici-
pants with spontaneous virus clearance, HLA-C genotyping was by
PCR and sequencing. All Australian samples were genotyped by
multiplex PCR for KIR2DL2 and KIR2DL3 [20]. KIR2DL2 and
KIR2DL3 in the remainder and in those participants with
spontaneous virus clearance and KIR2DS1 and KIR2DS2 in all
samples were genotyped by PCR using the protocol of Ashouri
et al. [21]. 2DL1 was not included owing to the fact that it is very
common (.90%), so we would have insufficient power to detect
an association with its absence. The rs8099917 SNP was
genotyped as previously reported [5]. The IL28B rs12979860
SNP was genotyped using a custom made Taqman genotyping kit.
Further details are reported in Text S1.
Statistical Analysis
The Mann-Whitney and chi-squared tests were used to analyze
baseline covariates. A chi-squared test was used to examine
differences in allele, carriage, and genotype frequencies between
SVR versus non-SVR (NSVR), those participants with spontane-
ous virus clearance (SC) versus CHC (i.e., NSVR plus SVR), and
viral clearance (SC plus SVR) versus NSVR. The relationships
between HLA-C, IL28B, and the KIR loci were investigated using
Prediction of Control of HCV
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logistic regression for predicting failure of SVR. Significance of all
models was assessed by likelihood ratio (LR) tests. Analysis was
carried out in R (v2.12).
Results
IL28B Genotype and HCV Viral Clearance
We had previously shown that the IL28B rs8099917 G allele
predicts failure to clear HCV on PegIFN/R therapy [5], in the
CHC cohort now analysed here for HLA-C and KIR genotypes.
Carriers of the G allele were under-represented in SC (odds ratio
[OR] 0.26, p=1.71610214, 2.67–5.48) (Tables 2 and S1). The G
allele appears to have a dominant effect, with both heterozygotes
(OR 3.42, p=1.32610211, 2.36–4.96) and homozygotes (OR
3.25, p=1.7861022, 1.16–9.10) being similarly more likely to fail
to clear virus spontaneously. SNP rs8099917 G carriers were
19.7% of SC, 27.5% of healthy controls (HapMap CEU [Utah
residents with Northern or Western European ancestry] data),
37.9% of SVR, and 57.3% of NSVR (Table S1). Overall, those
who failed to clear the virus after therapy or without therapy
(NSVR versus SVR and SC) were much less likely to have the
rs8099917 TT genotype (OR 0.34, p=1.44610217) (Table S1),
with both heterozygotes (OR 2.59, p=5.91610214) and homozy-
gotes (OR 2.12, p=7.5461023) for the G allele more likely to fail
to clear virus.
HLA-C2C2 Predicts Poor Viral Clearance on Therapy
The HLA-C1 and C2 variants are associated with a number of
aspects of viral clearance. HLA-C2 homozygotes were more likely
to fail to clear virus on therapy than other genotypes (OR 1.52,
p=0.025, 1.05–2.20) (Figure 1; Table 2). The HLA-C effect on
viral clearance seems to be a recessive trait, such that C1
heterozygotes are no more susceptible to treatment failure than C1
homozygotes. HLA-C2 homozygosity was not different between
those participants with spontaneous virus clearance and healthy
European controls (data for healthy controls from [22,23]) (see
Table S2). This important observation suggests that the difference
in association of HLA-C genotype with viral clearance is due to
response to therapy alone, not to the immune response in the
absence of therapy. From two-digit genotyping of HLA-C, the C2
variant conferring highest susceptibility to treatment failure is
Cw*05 (OR 1.43, p=0.047, 1.0–2.03) (Table S3). The Cw*03
variant of C1 confers significant drug response (OR 0.61,
p=1.6461023, 0.44–0.83).
Effect of KIR Genes on Viral Clearance
We tested if KIR2DL2 or 2DL3 affected response to therapy,
protection against development of CHC, or clearance of virus with
or without PegIFN/R (Table S4). As reported by others [13,14],
we observed no effect of KIR genotype per se on viral clearance in
any comparison. There was evidence of a similar trend between
homozygosity of HLA-C1 and KIR2DL3 with SVR [14], and with
spontaneous clearance [13]. Consistent with Knapp et al. [14] and
Khakoo et al. [13], we found evidence that those infected with
HCV and with the KIR2DL3/C2C2 genotype, were more likely to
fail to clear virus (OR 1.91, p=0.022, 1.09–3.36) (Table S5) on
therapy (NSVR versus SVR), and more common in those who
failed to clear virus on therapy (NSVR) compared to those who did
combined with those who cleared HCV without therapy
(SVR+SC) (OR 2.08, p=3.0061023, 1.27–3.40).
We next tested the combination of HLA-C alleles with KIR2DL3
and 2DL2 genes (Table S6). There was evidence of increased
association with the complementary pairs, so that the combination
of the C1 variant Cw*03 with its inhibiting genes was associated
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with increased treatment response: Cw*03 alone OR is 0.61
(p=1.6461023, 0.44–0.83), with 2DL2 is 0.47 (p=1.1961023,
0.29–0.75), with 2DL3 is 0.49 (p=2.1361024, 0.33–0.72). Most of
the C2 association with treatment failure was due to allele Cw*05
(OR 1.43, p=4.6661022, 1.0–2.03), with a larger effect in
combination with the inactivating haplotype tagged by 2DL3 (OR
1.97, p=2.0461023, 1.28–3.06), but unaffected by 2DL2.
Effect of Activating KIR Genes on Viral Clearance
The KIR ligands on NK cells activated on ligation to HLA-C
are KIR2DS2 for HLA-C1, and KIR2DS1 for HLA-C2.
Increased activation could occur in HLA-C1 carriers who are also
carriers of KIR2DS2, and for HLA-C2 carriers who are also carriers
of KIR2DS1. However, we found no evidence that KIR2DS
genotypes affected viral clearance either singly or in combination
with HLA-C genotypes (Tables S7 and S8), although from a logistic
regression model, it seems that KIR2DS1 could mitigate the effect
of HLA-C2C2 (see below).
Combined Effect of HLA-C and IL28B Genotypes
Prediction of failure to clear HCV in response to treatment with
either IL28B or HLA-C genotypes alone is of limited value
clinically due to the relatively low positive predictive value (PPV)
for treatment failure [24]. We therefore tested if both genotypes
together provided additional power to predict response. Indeed,
the combination significantly improves prediction of failure to
clear virus on therapy (OR 3.78, p=8.8361026, 2.03–7.04),
failure to clear virus spontaneously (OR 7.31, p=1.2761023,
1.78–30.06), and failure to clear virus with and without therapy
(OR 5.10, p=2.5361029, 2.84–9.17) (Tables 2 and S9a). The
largest difference was between those participants with spontaneous
virus clearance and those who failed to clear virus on therapy
(Figure 2). As shown in Table 3, prediction of treatment failure
improved from 66% for IL28B G to 80% with IL28B G*/C2C2.
A similar predictive value for treatment response has been
reported for IL28B SNP rs12979860[4] We found that the PPV
derived from combining this SNP and HLA-C2C2 was actually
lower in this cohort than for the rs8099917 combination (OR 2.52,
p=5.1861025, 1.59–3.98) (Table S9b). Adding the clinical
features of age, gender, body mass index, or viral load improved
predictive value (Figure S1, responder operator curves).
Table 2. Association of IL28B rs8099917 and HLA-C genotypes with viral clearance on therapy and spontaneous clearance.
Cohort IL28 HLA-C IL28/HLA-C
a
TT TG GG C1C1 C1C2 C2C2 C1*TT C2C2 G*
SVR
(n=398/390/389)b
247 (62.0) 134 (33.7) 17 (4.3) 151 (38.7) 185 (47.4) 54 (13.8) 200 (51.4) 13 (3.3)
NSVR
(n=475/463/459)b
203 (42.7) 239 (50.3) 33 (6.9) 180 (38.9) 192 (41.5) 91 (19.7) 160 (34.9) 53 (11.5)
p-Value 1.2761028 7.3561027 0.090 1.0 0.084 0.024 1.1761026 8.8361026
OR, 95% CI 0.46,
0.35–0.60
2.0,
1.52–2.63
1.52,
1.05–2.20
0.51,
0.38–0.67
3.78,
2.03–7.04
Participants with
spontaneous virus
clearance
(n=218/228/212)a
175 (80.3) 39 (17.9) 4 (1.8) 95 (41.7) 105 (46.1) 28 (12.3) 147 (69.3) 2 (0.9)
CHC
(n=873/853/848)c
450 (51.5) 373(42.7) 50(5.7) 331(38.8) 377(44.2) 145(17.0) 360 (42.5) 69 (6.5)
p-Value 1.71610214 1.32610211 0.018 0.43 0.62 0.084 2.40610212 1.2761023
OR, 95% CI 0.26,
0.18–0.37
3.42,
2.36–4.96
3.25,
1.16–9.10
0.33,
0.24–0.45
7.31,
1.78–30.06
Since the HLA-C genotype effect appears to be recessive, and IL28B genotype effect dominant, the genotypes of maximal difference are shown. C1*, C1 carriers; G*, G
carriers. Comparisons with p,0.05 are in bold.
aTable S2 shows the data for all genotypes.
bThree different n represent the three sets of genotyping results being compared in this table, respectively.
doi:10.1371/journal.pmed.1001092.t002
Figure 1. Association of HLA-C genotype with viral clearance
with and without therapy. OR is plotted against viral clearance for
each comparison, plus or minus 95% confidence interval (CI). Vertical
height of plotted points is in proportion to log (1/p) where ‘‘p’’ is the
probability of observed association being by chance. ORs are shown for
each comparison. G*, carrier of G allele.
doi:10.1371/journal.pmed.1001092.g001
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Interactions between IL28B, HLA-C, and KIR
Using a logistic regression model, the increased OR of 3.78 for
the combination rs8099917, G*/C2C2 is partially due to genetic
interaction (LR, p,0.05) (Table S10), and not just an additive
effect. Examining the relationship between KIR genotype and
either HLA-C2C2 or IL28B rs8099917 G*, we found no evidence
for any two-way interactions for predicting failure of SVR. For the
three-way interaction model between HLA-C, IL28, and not
2DS1, although the coefficient for the three-way interaction is
significant, the LR test concludes that the model does not produce
a significantly better fit (LR, p=0.28). Although the HLA-C main
effect is not significant via a standard t-test in the interaction
model, it is associated with response (Table 2). Adding HLA-C to a
model including rs8099917 leads to significant improvement of the
fit (LR, p=0.006), implying that HLA-C has an independent affect
on response and should be included in the model. Adding the
interaction term again improves the model fit (LR, p=0.03).
Discussion
The IL28B genotype is already used to predict treatment
response to PegIFN/R in clinical practice, even though its
association with therapeutic response was only first identified in
late 2009. We tested the IL28B, HLA-C, and KIR gene variant
associations with treatment-induced and spontaneous clearance
of HCV and confirmed that IL28B rs8099917 predicts clearance
in both situations. The HLA-C2C2 genotype predicted failure to
clear HCV on treatment, but no association with failure to clear
HCV without treatment was detected. The prediction of
treatment-induced clearance was additive and interactive
between IL28B and HLA-C; and there was evidence of additive
and interactive effects between KIR2DL3, KIR2DS1, and HLA-
C2C2. These data and previous reports point to HLA-C as being
the second gene predicting PegIFN/R treatment response in
HCV. This genetic evidence supports an underlying physiolog-
ical mechanism for HCV viral control involving an interaction
between IL28B, HLA-C, and KIRs.
Khakoo et al. [13] and Dring et al. [25] compared HLA-C and
KIR genotypes between those participants with spontaneous virus
clearance and CHC, and Knapp et al. [14] in these and in
treatment response. As in our study, Khakoo et al. reported
HLA-C2 homozygotes were more common in CHC than SC
(OR 1.49, p= 0.02), and KIR2DL3-C2 homozygotes slightly more
so (OR 1.87, p= 0.01); and Dring et al. reported KIR2DS3-C2
carriers were more common in CHC than SC (OR 2.26,
p=0.002). Knapp et al. detected a trend towards C2 excess in
those who failed to clear virus spontaneously compared to CHC
(OR 1.69, p=0.10), a trend of C2 excess in NSVR versus SVR
(OR 1.38, p= 0.27) [13], but no difference between SVR and
SC. In both the Knapp study and ours, the KIR2DL3-C1
homozygotes were more common in SVR, and most of this
association was due to the C1-Cw*03 variant. KIR2DL3 tags
haplotype A, which contains fewer activating KIR genes. This
association is consistent with insufficient activation of NK cells in
the context of HLA-C2C2 inhibition as the basis for increased
risk of treatment failure.
Dring et al. [25] identified a dramatic synergy between
KIR2DS3 (not examined here, encoded on haplotype B) and
the IL28B SNP rs12979860 in predicting spontaneous clearance in
a unusually homogenous cohort of Irish females infected with
genotype 1 HCV by transfusion. They also showed that IFNl
inhibited IFNc production by NK cells. They did not examine
SNP rs8099917 or SVR and NSVR. Their data further support
NK function in HCV clearance as being influenced by IFNl.
Because of the very high linkage disequilibrium in the MHC
class I region around HLA-C, the association we and others have
observed may be due to HLA-C variants tagging other class I
genes. However, the KIR interactions, which are HLA-C specific,
support the signal being due to HLA-C itself, as does the strong
body of evidence pointing to the importance of NK cells in killing
virally infected cells in response to interferon and tumor necrosis
factor-alpha-related apoptosis-inducing ligand (TRAIL) (reviewed
in [26–28]). In addition, activated NK cells recognize and lyse
HCV replicon-containing hepatoma cells in vitro [27] and should
therefore be able to kill virus-infected hepatocytes in vivo. Cells
that lack or have downregulated MHC class I molecules, such as
virally infected cells or tumour cells, are susceptible to NK cell-
mediated killing. In this context it has been reported that IFNl3
(the protein encoded by IL28B) augments the antitumor activity of
NK cells [11,27].
The association of HLA-C with viral clearance on treatment but
not spontaneous clearance suggests that, on therapy, NK killing of
hepatocytes is augmented in HLA-C1 carriers compared to C2
homozygotes. There are numerous potential mechanisms by
which HLA-C genotypes could affect NK cell activity in the
context of IFNa treatment. IFNa could affect NK killing of HCV-
infected hepatocytes. IFNa is known to increase NK sensitivity to
activation [27], but also to directly activate NK cells in patients
Table 3. Prediction of failure to clear virus on therapy with
PegIFN/R.
Genotype Sensitivity Specificity
Positive
Predictive
Value
Negative
Predictive
Value
IL28GG 7 96 66 46
IL28G* 57 62 64 55
HLA-C2C2 20 86 63 47
HLA C2* 61 39 54 46
IL28G*/HLA-
C2C2
12 97 80 48
Positive predictive value and negative predictive value for best genotype are in
bold.
doi:10.1371/journal.pmed.1001092.t003
Figure 2. Proportion of each cohort with the HLA-C2C2 and
IL28B G* genotype, which predicts treatment failure. HC,
healthy controls; G*, carrier of G allele. Lines connect the significant
262 chi-squared comparisons with associated p-values and ORs. HC
numbers obtained from Williams et al. [23] and Dunne
et al. [22].
doi:10.1371/journal.pmed.1001092.g002
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with HCV infection and induced a strongly cytotoxic phenotype
[27]. This NK cell activation and killing of hepatocytes is affected
by the HLA-C genotype: the C1 allele allowing activation more
rapidly and aggressively [16]. HLA-C may be even more
upregulated in response to IFNa [29], making it more difficult
for C2 homozygotes to activate NK cells.
The association of IL28B genotype with SC and therapeutic
response indicates that IFNl3 affects viral clearance. IFNl3 is likely
to enhance antiviral mechanisms through upregulation of interfer-
on-stimulated genes (ISGs) in acute disease [24], but its effect may
be more complicated in chronic infection, in which upregulation of
ISGs in liver is associated with reduced treatment response [30].
One approach to identifying the molecular pathways through which
a genetic variant affects disease outcome is to identify other genes
that affect pathogenesis, and especially those with which it may
interact. The additive association of HLA-C and IL28B genotypes
with treatment-induced clearance, but not spontaneous clearance,
suggests IL28B may be enhancing NK killing on PegIFN/R
therapy. HLA-C is one of the most upregulated genes following
treatment of a cell line with IFNl3 [29]. The degree of this
upregulation may depend on HLA-C genotype.
The larger predictive value for HLA-C2C2 and IL28B
rs8099917 G* than SNP rs12979860 T* may indicate different
haplotype effects. There are five common IL28B haplotypes in
Caucasians [5]. The rs8099917 minor allele tags the haplotype
with the highest association with therapeutic response, whilst
rs12979860 minor alleles are on this haplotype and others (Table
S11). Ge et al. [4] reported that there was evidence of independent
effects of the two haplotypes. Therefore the additive effect of HLA-
C with IL28B may be only with the rs8099917-tagged haplotype. It
is likely that these two SNPs, which were on genotyping chips, will
be supplanted by others when a more comprehensive analysis of
the genetic variation of IL28B is available.
The overall differences in frequency of HLA-C2C2/IL28B G*
in healthy controls, those participants with spontaneous virus
clearance, SVR, and NSVR groups suggests a role in pathogenesis
for this gene combination. It is also striking that HLA-C2C2
frequency is highly variable between ethnic groups, roughly in
proportion to their treatment responsiveness (Figure S2). Much of
the variation between African Americans and European Ameri-
cans has been explained by the IL28B rs12979860 SNP [4], but it
seems likely that the higher proportion of the HLA-C2C2 genotype
in African Americans may also contribute to their reduced viral
clearance.
With regard to patient management, avoiding treatment in
those less likely to respond to PegIFN/R is important given the
toxicity of this treatment and the likelihood that one or multiple
direct acting antiviral agents will soon be available [31,32]. In this
context, IL28B genotype alone allows prediction of failure of
PegIFN/R in only 66% of patients (Table 3). We have shown that
with HLA-C genotyping this can be improved to a clinically more
meaningful 80%. Genotyping of IL28B and HLA-C to C1/C2 is
rapid and inexpensive. Further genetic associations, including
those affecting HLA-C/IFNl interactions, viral sequence vari-
ability [33], and host/virus interactions such as IP-10 levels [34]
might further enhance prediction of treatment outcomes.
In addition to supporting the importance of HLA-C, KIR, and
IL28B in HCV clearance and drug response, and emphasizing the
role of NK cells in the outcomes of HCV infection, this study
highlights the value of investigating variants other than SNPs to
identify genetic variants causing disease and drug response.
Notably, independent replication of these data in Europeans,
and testing them for the first time in African-Americans and other
ethnic groups is required.
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Editors’ Summary
Background. About 170 million people harbor long-term
(chronic) infections with the hepatitis C virus (HCV) and 3–4
million people are newly infected with the virus every year.
HCV—a leading cause of chronic hepatitis (inflammation of
the liver)—is spread though contact with infected blood.
Transmission can occur during medical procedures (for
example, transfusions with unscreened blood or reuse of
inadequately sterilized medical instruments) but in
developed countries, where donated blood is routinely
screened for HCV, the most common transmission route is
needle-sharing among intravenous drug users. HCV infection
can cause a short-lived illness characterized by tiredness and
jaundice (yellow skin and eyes) but 70%–80% of newly
infected people progress to a symptom-free, chronic
infection that can eventually cause liver cirrhosis (scarring)
and liver cancer. HCV infections can be treated with a
combination of two drugs—pegylated interferon-alpha and
ribavirin (PegIFN/R). However, PegIFN/R is expensive, causes
unpleasant side-effects, and is ineffective in about half of
people infected with HCV genotype 1, the commonest HCV
strain.
Why Was This Study Done? It would be extremely helpful
to be able to identify which patients will respond to PegIFN/
R before starting treatment. An individual’s genetic make-up
plays a key role in the safety and effectiveness of drugs. Thus,
pharmacogenomics—the study of how genetic variants
affects the body’s response to drugs—has the potential to
alter the clinical management of many diseases by allowing
clinicians to provide individually tailored drug treatments. In
2009, scientists reported that certain single nucleotide
polymorphisms (SNPs, a type of genetic variant) lying near
the IL28B gene (which encodes an immune system protein
made in response to viral infections) strongly influence
treatment outcomes and spontaneous clearance in HCV-
infected people. This discovery is now being used to predict
treatment responses to PegIFN/R in clinical practice but
genotyping (analysis of variants of) IL28B only correctly
predicts treatment failure two-thirds of the time. Here, the
researchers investigate whether genotyping two additional
regions of the genome—the HLA-C and KIR gene loci—can
improve the predictive value of IL28B genotyping. Human
leukocyte antigen C (HLA-C) and the killer immunoglobulin-
like receptors (KIRs) are interacting proteins that have been
implicated in HCV viral control.
What Did the Researchers Do and Find? The researchers
genotyped 417 patients chronically infected with HCV
genotype 1 whose infection had been cleared by PegIFN/R
treatment, 493 patients whose infection had not responded
to treatment, and 234 patients whose infection had cleared
spontaneously for two HLA-C variants (C1 and C2), the
presence of several KIR genes (individuals carry different
combinations of KIR genes), and two IL28B SNPs (rs8099917
and rs12979860). Carriage of ‘‘variants’’ of either IL28B SNP
was associated with absence of treatment-induced clearance
and absence of spontaneous clearance. That is, these variant
SNPs were found more often in patients who did not
respond to treatment than in those who did respond, and
more often in patients who did not have spontaneous
clearance of their infection than those who did. The HLA-C
C2C2 genotype (there are two copies of most genes in the
genome) was also more common in patients who failed
treatment than in those who responded but was not
associated with spontaneous clearance. The rate of correct
prediction of treatment failure increased from 66% with
IL28B genotyping alone to 80% with combined IL28B and
HLA-C genotyping. Finally, carriage of specific KIR genes in
combination with specific HLA-C and IL28B variants was also
associated with an altered HCV treatment response.
What Do These Findings Mean? These findings show
that the addition of HCL-C and KIR genotyping to IL28B
genotyping improved the prediction of HCV treatment
response in the patients investigated in this study. Because
all these patients were European or of European descent,
these findings need confirming in people of other ethnic
backgrounds. They also need confirming in other groups of
Europeans before being used in a clinical setting. However,
the discovery that the addition of HLA-C genotyping to IL28B
genotyping raises the rate of correct prediction of PegIFN/R
treatment failure to 80% is extremely promising and should
improve the clinical management of patients infected with
HCV genotype 1. In addition, these results provide new
insights into how PegIFN/R clears HCV infections that may
lead to improved therapies in the future.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001092.
N The World Health Organization provides detailed informa-
tion about hepatitis C (in several languages)
N The US Centers for Disease Control and Prevention
provides information on hepatitis C for the public and
for health professionals (information is also available in
Spanish)
N The US National Institute of Diabetes and Digestive and
Kidney Diseases provides basic information on hepatitis C
(in English and Spanish)
N The Hepatitis C Trust is a patient-led, patient-run UK charity
that provides detailed information about hepatitis C and
support for patients and their families; a selection of
personal stories about patients’ experiences with hepatitis
C is available, including Phil’s treatment story, which
details the ups and downs of treatment with PegIFN/R
N MedlinePlus provides links to further resources on hepatitis
C
N The Human Genome Project provides information about
medicine and the new genetics, including a primer on
pharmacogenomics
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